Merck Seeks To Boot Fosamax Plaintiffs, Experts

Law360, New York (May 11, 2009, 12:00 AM EDT) -- Merck & Co. Inc. is seeking to throw out the claims of 26 plaintiffs in the multidistrict litigation over its osteoporosis drug Fosamax and also wants a judge to exclude certain plaintiffs' experts from three lead cases in the litigation.

In court documents filed Friday, Merck asked Judge John F. Keenan of the U.S. District Court for the Southern District of New York to grant summary judgment on all claims advanced by the specific plaintiffs, who claim they developed a bone degenerative disease known as osteonecrosis...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.